Wright Medical Group, Inc. (NASDAQ: WMGI) today announced that Pascal E.R. Girin has been appointed Executive Vice President and Chief Operating Officer. In this newly created position, Mr. Girin will have global operating responsibility for Wright's Extremities, OrthoRecon and International businesses and Clinical, Regulatory and Quality, reporting directly to the Chief Executive Officer. Mr. Girin’s first day of employment will be the later of November 19, 2012 or the date the transfer of his visa is finalized.
“I'm delighted to announce Pascal’s appointment to this new position to lead our global businesses,” stated Robert Palmisano, President and Chief Executive Officer of Wright Medical. “Pascal is a proven leader with significant operational experience. While working with me at ev3, Pascal was a major contributor to the company’s growth and success, including the rapid expansion of ev3’s worldwide neurovascular business to the #2 overall revenue share position, the successful acquisition of Chestnut Medical, and the growth of ev3’s peripheral vascular and international businesses at rates that significantly outpaced the market.”
Palmisano continued, “In addition to Pascal’s appointment, we have made some important changes to the way our business is organized and structured. In the U.S., we will now have an Extremities division and an OrthoRecon division. In conjunction with this new structure, I’m pleased to announce the promotion of Eric Stookey to be the President of the Extremities division and Ted Davis to be the President of the OrthoRecon division. Both Eric and Ted will report to Pascal Girin in his newly created role of Executive Vice President and Chief Operating Officer. During their tenure with Wright, both Eric and Ted have demonstrated their knowledge of our markets, their understanding of our customers and their leadership within the company. I’m confident that Pascal’s appointment, as well as our new structure, will further bolster our ability to capitalize on the growth opportunities in front of us and accelerate our market performance.”